These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25131433)

  • 41. Cardiovascular pathobiology of inflammasomes: inflammatory machinery and beyond.
    Li PL
    Antioxid Redox Signal; 2015 May; 22(13):1079-83. PubMed ID: 25779752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of the NLRP3 inflammasome in pulmonary diseases.
    Hosseinian N; Cho Y; Lockey RF; Kolliputi N
    Ther Adv Respir Dis; 2015 Aug; 9(4):188-97. PubMed ID: 26012351
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Role of Inflammasome in Children's Immune Thrombocytopenia].
    Li M; Qiao J; Wang DD; Liang DD; Chen W; Sun HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1742-1745. PubMed ID: 30501714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Inflammasome and cardiovascular diseases].
    Connat JL
    Ann Cardiol Angeiol (Paris); 2011 Feb; 60(1):48-54. PubMed ID: 20800829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical analysis of rituximab-induced interstitial lung disease].
    Huang C; Lu ZW; Yang YQ; Chen H; Huang DP; He HS
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):730-735. PubMed ID: 29050126
    [No Abstract]   [Full Text] [Related]  

  • 46. [The NLRP3 inflammasome: Physiopathology and therapeutic application].
    Gicquel T; Robert S; Victoni T; Lagente V
    Presse Med; 2016 Apr; 45(4 Pt 1):438-46. PubMed ID: 26880081
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases.
    Sayan M; Mossman BT
    Part Fibre Toxicol; 2016 Sep; 13(1):51. PubMed ID: 27650313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.
    Malhotra S; Río J; Urcelay E; Nurtdinov R; Bustamante MF; Fernández O; Oliver B; Zettl U; Brassat D; Killestein J; Lechner-Scott J; Drulovic J; Chan A; Martinelli-Boneschi F; García-Merino A; Montalban X; Comabella M
    Brain; 2015 Mar; 138(Pt 3):644-52. PubMed ID: 25586466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease.
    De Nardo D; De Nardo CM; Latz E
    Am J Pathol; 2014 Jan; 184(1):42-54. PubMed ID: 24183846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Crucial Role of NLRP3 Inflammasome in Viral Infection-Associated Fibrosing Interstitial Lung Diseases.
    Effendi WI; Nagano T
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.
    Liu X; Hong XN; Gu YJ; Wang BY; Luo ZG; Cao J
    Leuk Lymphoma; 2008 Sep; 49(9):1778-83. PubMed ID: 18798110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Changes of Inflammasome in Children with Immune Thrombocytopenia before and after Treatment].
    Chen W; Qiao J; Zong SF; Liang DD; Sun HM; Li M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1566-1569. PubMed ID: 34627441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Inflammasome: activation mechanisms].
    Suárez R; Buelvas N
    Invest Clin; 2015 Mar; 56(1):74-99. PubMed ID: 25920188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation.
    Xu JF; Washko GR; Nakahira K; Hatabu H; Patel AS; Fernandez IE; Nishino M; Okajima Y; Yamashiro T; Ross JC; Estépar RS; Diaz AA; Li HP; Qu JM; Himes BE; Come CE; D'Aco K; Martinez FJ; Han MK; Lynch DA; Crapo JD; Morse D; Ryter SW; Silverman EK; Rosas IO; Choi AM; Hunninghake GM;
    Am J Respir Crit Care Med; 2012 Mar; 185(5):547-56. PubMed ID: 22246178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab may cause higher mortality in young autoimmune disease patients with rituximab-induced interstitial lung disease: A case report and systematic review of the literature.
    He Z; Wu R; Bai P; Qiu K
    Int J Clin Pharmacol Ther; 2020 Dec; 58(12):740-748. PubMed ID: 32909538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-infectious pulmonary toxicity of rituximab: a systematic review.
    Hadjinicolaou AV; Nisar MK; Parfrey H; Chilvers ER; Ostör AJ
    Rheumatology (Oxford); 2012 Apr; 51(4):653-62. PubMed ID: 22157468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular activation of the NLRP3 Inflammasome in fibrosis: common threads linking divergent fibrogenic diseases.
    Artlett CM; Thacker JD
    Antioxid Redox Signal; 2015 May; 22(13):1162-75. PubMed ID: 25329971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituximab in severe, treatment-refractory interstitial lung disease.
    Keir GJ; Maher TM; Ming D; Abdullah R; de Lauretis A; Wickremasinghe M; Nicholson AG; Hansell DM; Wells AU; Renzoni EA
    Respirology; 2014 Apr; 19(3):353-9. PubMed ID: 24286447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced Activity of NLRP3 Inflammasome in the Lung of Patients with Anti-Synthetase Syndrome.
    Ramos-Martinez E; Vega-Sánchez AE; Pérez-Rubio G; Mejia M; Buendía-Roldán I; González-Pérez MI; Mateos-Toledo HN; Andrade WA; Falfán-Valencia R; Rojas-Serrano J
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611853
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hijacking the NLRP3 inflammasome: a mechanism underlying viral respiratory disease?
    Zhang Z; Ricci R
    EMBO Rep; 2020 Jul; 21(7):e50645. PubMed ID: 32419206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.